9 Quotes by Anthony Butler

Thus, if the consumer business were to be sold, or perhaps restructured into a JV contributing below Pfizer's operating line, it would likely have the effect of increasing gross margins and operating margins.

While Pfizer's cash flow would likely be impacted by the loss or change in structure, we note that a partnership with another consumer health business could create increased clout for shelf space and thus operate with new synergies.

There's no evidence that the amount of payment will ever exceed the amount of cash, ... Nobody's had to cut their dividend because of liability.

There's a rarely a day that goes by where there's not a negative story about a drug company. The only thing that's been delivered to the public is negative information, and it leaves the public with a sorry taste in its mouth.

It strikes me as being unique that a company can see half a billion dollars in income go away and see it as a relatively small impact on earnings per share.

Does it increase the amount of money for which Merck is liable? I would say no, because Merck hasn't been proven to be liable for anything.

Does it increase the amount of money for which Merck is liable? ... I would say no, because Merck hasn't been proven to be liable for anything.

It's certainly not a shock to me, and I don't think it would be a shock to anyone on Wall Street that the number of lawsuits has increased.

The entire drug group is not exactly having a stellar performance and may not until the second half of 2002 when we expect a number of positive catalysts, in the form of drug approvals, to emerge within the sector,